Skip to main content
Top
Published in: Pain and Therapy 1/2018

Open Access 01-06-2018 | Review

A Review of the Opioid Epidemic: What Do We Do About It?

Authors: Edward A. Shipton, Elspeth E. Shipton, Ashleigh J. Shipton

Published in: Pain and Therapy | Issue 1/2018

Login to get access

Abstract

The opioid epidemic, with its noticeable increase in opioid prescriptions and related misuse, abuse and resultant deaths in the previous 12 years, is a particularly North American phenomenon. Europe, and particularly low- and middle-income countries, appear to be less influenced by this problem. There is undisputable value in using opioids not only in the treatment of acute pain, but in cancer pain as well. However, opioids are progressively being prescribed more and more for chronic non-cancer pain, despite inadequate data on their efficacy. In this paper, we describe the current prevalence of opioid misuse in a number of countries and the rationale for the commencement of opioid therapy. The safe initiation and monitoring of opioid therapy as well as the need for concurrent use of interdisciplinary multimodal therapy is discussed. The possible consequences of long-term use and predictors of high opioid use and overdose are presented. In particular, the management of opioid use disorders and the prevention of opioid abuse and dependence in the young, the old and the pregnant are discussed. Measures to prevent overprescribing and to alleviate risk are described, including the tapering of opioids and the use of opioid deterrents. Finally, the paper looks at the future development of pioneering medications and technologies to potentially treat abuse. In those parts of the world with an opioid epidemic, coroners and medical examiners, private and public health agencies, and agencies that enforce the law need to cooperate in an effort to slow down and reverse the indiscriminate use of prescribing opioids in the long-term for chronic non-cancer pain. Ongoing research is needed to create ways to minimise risks of opioid use, and to provide evidence for effective strategies for treating chronic pain.
Literature
3.
go back to reference Häuser W, Wolfe F, Henningsen P, Schmutzer G, Brähler E, Hinz A. Untying chronic pain: prevalence and societal burden of chronic pain stages in the general population—a cross-sectional survey. BMC Public Health. 2014;14:352.CrossRefPubMedPubMedCentral Häuser W, Wolfe F, Henningsen P, Schmutzer G, Brähler E, Hinz A. Untying chronic pain: prevalence and societal burden of chronic pain stages in the general population—a cross-sectional survey. BMC Public Health. 2014;14:352.CrossRefPubMedPubMedCentral
4.
go back to reference Andrew R, Derry S, Taylor RS, et al. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Pract. 2014;14:79–94.CrossRefPubMed Andrew R, Derry S, Taylor RS, et al. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Pract. 2014;14:79–94.CrossRefPubMed
5.
go back to reference Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open. 2016;6(6):e010364.CrossRefPubMedPubMedCentral Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open. 2016;6(6):e010364.CrossRefPubMedPubMedCentral
6.
go back to reference Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521–7.CrossRefPubMed Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521–7.CrossRefPubMed
7.
go back to reference Clark DJ, Schumacher MA. America’s opioid epidemic: supply and demand considerations. Anesth Analg. 2017;125(5):1667–74.CrossRefPubMed Clark DJ, Schumacher MA. America’s opioid epidemic: supply and demand considerations. Anesth Analg. 2017;125(5):1667–74.CrossRefPubMed
8.
go back to reference Lamvu G, Feranec J, Blanton E. Perioperative pain management: an update for obstetrician–gynecologists. Am J Obstet Gynecol. 2018;218(2):193–9.CrossRefPubMed Lamvu G, Feranec J, Blanton E. Perioperative pain management: an update for obstetrician–gynecologists. Am J Obstet Gynecol. 2018;218(2):193–9.CrossRefPubMed
9.
go back to reference Häuser W, Petzke F, Radbruch L, Tölle TR. The opioid epidemic and the long-term opioid therapy for chronic noncancer pain revisited: a transatlantic perspective. Pain Manag. 2016;6(3):249–63.CrossRefPubMed Häuser W, Petzke F, Radbruch L, Tölle TR. The opioid epidemic and the long-term opioid therapy for chronic noncancer pain revisited: a transatlantic perspective. Pain Manag. 2016;6(3):249–63.CrossRefPubMed
10.
go back to reference Häuser W, Schug S, Furlan AD. The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents. Pain Rep. 2017;2(3):e599.CrossRefPubMedPubMedCentral Häuser W, Schug S, Furlan AD. The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents. Pain Rep. 2017;2(3):e599.CrossRefPubMedPubMedCentral
11.
go back to reference Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Raffa RB, NEMA Research Group. Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin. Postgrad Med. 2018;130(1):1–8.CrossRefPubMed Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Raffa RB, NEMA Research Group. Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin. Postgrad Med. 2018;130(1):1–8.CrossRefPubMed
13.
go back to reference Chang KC, Wang JD, Saxon A, Matthews AG, Woody G, Hser YI. Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan. Int J Drug Policy. 2017;43:1–6.CrossRefPubMedPubMedCentral Chang KC, Wang JD, Saxon A, Matthews AG, Woody G, Hser YI. Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan. Int J Drug Policy. 2017;43:1–6.CrossRefPubMedPubMedCentral
14.
go back to reference Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–52.CrossRefPubMed Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–52.CrossRefPubMed
15.
go back to reference Manchikanti L, Helm S, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician. 2012;15(3):9–38. Manchikanti L, Helm S, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician. 2012;15(3):9–38.
17.
go back to reference Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–6.CrossRefPubMedPubMedCentral Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–6.CrossRefPubMedPubMedCentral
18.
go back to reference Manchikanti L, Boswell MV, Hirsch JA. Lessons learned in the abuse of pain-relief medication: a focus on healthcare costs. Expert Rev Neurother. 2013;13(5):527–43.CrossRefPubMed Manchikanti L, Boswell MV, Hirsch JA. Lessons learned in the abuse of pain-relief medication: a focus on healthcare costs. Expert Rev Neurother. 2013;13(5):527–43.CrossRefPubMed
20.
go back to reference Dispensing of prescription opioids in Canada has increased steadily since 2000, from 10,209 defined daily doses per million population per day in 2001–2003 to 30,540 in 2012–2014. International Narcotics Control Board (INCB) Narcotic drugs: estimated world requirements for 2004, statistics for 2002. United Nations Publication Sales. 2004;No.T:.16.XI.2. Dispensing of prescription opioids in Canada has increased steadily since 2000, from 10,209 defined daily doses per million population per day in 2001–2003 to 30,540 in 2012–2014. International Narcotics Control Board (INCB) Narcotic drugs: estimated world requirements for 2004, statistics for 2002. United Nations Publication Sales. 2004;No.T:.16.XI.2.
21.
go back to reference International Narcotics Control Board (INCB) Narcotic drugs: estimated world requirements for 2016—statistics for 2014. United Nations Publication Sales. 2016;No. T:16.XI.2. International Narcotics Control Board (INCB) Narcotic drugs: estimated world requirements for 2016—statistics for 2014. United Nations Publication Sales. 2016;No. T:16.XI.2.
22.
go back to reference Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A, Cooper L, Cull C, da Costa BR, Frank JW, Grant G, Iorio A, Persaud N, Stern S, Tugwell P, Vandvik PO, Guyatt GH. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18):E659–66.CrossRefPubMedPubMedCentral Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A, Cooper L, Cull C, da Costa BR, Frank JW, Grant G, Iorio A, Persaud N, Stern S, Tugwell P, Vandvik PO, Guyatt GH. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18):E659–66.CrossRefPubMedPubMedCentral
26.
go back to reference Pergolizzi JV Jr, LeQuang JA, Berger GK, Raffa RB. The basic pharmacology of opioids informs the opioid discourse about misuse and abuse: a review. Pain Ther. 2017;6(1):1–16.CrossRefPubMedPubMedCentral Pergolizzi JV Jr, LeQuang JA, Berger GK, Raffa RB. The basic pharmacology of opioids informs the opioid discourse about misuse and abuse: a review. Pain Ther. 2017;6(1):1–16.CrossRefPubMedPubMedCentral
27.
go back to reference Schubert I, Ihle P, Sabatowski R. Increase in opiate prescription in Germany between 2000 and 2010: a study based on insurance data. Dtsch Arztebl Int. 2013;110:45–51.PubMedPubMedCentral Schubert I, Ihle P, Sabatowski R. Increase in opiate prescription in Germany between 2000 and 2010: a study based on insurance data. Dtsch Arztebl Int. 2013;110:45–51.PubMedPubMedCentral
28.
go back to reference Werber A, Marschall U, L’hoest HW, Moradi B, Schiltenwolf M. Opioid therapy in the treatment of chronic pain conditions in Germany. Pain Physician. 2015;18(3):E323–31.PubMed Werber A, Marschall U, L’hoest HW, Moradi B, Schiltenwolf M. Opioid therapy in the treatment of chronic pain conditions in Germany. Pain Physician. 2015;18(3):E323–31.PubMed
29.
go back to reference Reinecke H, Sorgatz H. S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz. 2009;23:440–7.CrossRefPubMed Reinecke H, Sorgatz H. S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz. 2009;23:440–7.CrossRefPubMed
30.
go back to reference Hauser W, Bock F, Engeser P, et al. Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain. Schmerz. 2015;29:109–30.CrossRefPubMed Hauser W, Bock F, Engeser P, et al. Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain. Schmerz. 2015;29:109–30.CrossRefPubMed
32.
go back to reference Cooper AJM, Willis J, Fuller J, Benecke H, Leighton-Scott J, Andersohn F, Kim J, Maier C, Knaggs RD. Prevalence and incidence trends for diagnosed prescription opioid use disorders in the United Kingdom. Pain Ther. 2017;6(1):73–84.CrossRefPubMedPubMedCentral Cooper AJM, Willis J, Fuller J, Benecke H, Leighton-Scott J, Andersohn F, Kim J, Maier C, Knaggs RD. Prevalence and incidence trends for diagnosed prescription opioid use disorders in the United Kingdom. Pain Ther. 2017;6(1):73–84.CrossRefPubMedPubMedCentral
33.
go back to reference Neutel CI, Skurtveit S, Berg C, Sakshaug S. Trends in prescription of strong opioids for 41–80 years old Norwegians, 2005–2010. Eur J Pain. 2014;18(3):438–46.CrossRefPubMed Neutel CI, Skurtveit S, Berg C, Sakshaug S. Trends in prescription of strong opioids for 41–80 years old Norwegians, 2005–2010. Eur J Pain. 2014;18(3):438–46.CrossRefPubMed
34.
go back to reference Shipton EE, Shipton AJ, Williman JA, Shipton EA. Deaths from opioid overdosing: implications of Coroners’ inquest reports 2008–2012 and annual rise in opioid prescription rates. Pain Therapy. 2017;6(2):203–15.CrossRefPubMedPubMedCentral Shipton EE, Shipton AJ, Williman JA, Shipton EA. Deaths from opioid overdosing: implications of Coroners’ inquest reports 2008–2012 and annual rise in opioid prescription rates. Pain Therapy. 2017;6(2):203–15.CrossRefPubMedPubMedCentral
35.
go back to reference Häuser W, Schubert T, Scherbaum N, Tölle T. Guideline-recommended vs high-dose long-term opioid therapy for chronic noncancer pain is associated with better health outcomes: data from a representative sample of the German population. Pain. 2018;159(1):85–91.CrossRefPubMed Häuser W, Schubert T, Scherbaum N, Tölle T. Guideline-recommended vs high-dose long-term opioid therapy for chronic noncancer pain is associated with better health outcomes: data from a representative sample of the German population. Pain. 2018;159(1):85–91.CrossRefPubMed
36.
go back to reference Jena AB, Goldman D, Weaver L, Karaca-Mandic P. Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims. BMJ. 2014;19(348):g1393.CrossRef Jena AB, Goldman D, Weaver L, Karaca-Mandic P. Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims. BMJ. 2014;19(348):g1393.CrossRef
37.
go back to reference Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on drug use and health: summary of national findings, NSDUH, MD. Rockville: Substance Abuse and Mental Health Services Administration; 2014. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on drug use and health: summary of national findings, NSDUH, MD. Rockville: Substance Abuse and Mental Health Services Administration; 2014.
38.
go back to reference Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use—United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66:265–9.CrossRefPubMedPubMedCentral Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use—United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66:265–9.CrossRefPubMedPubMedCentral
39.
go back to reference Cheatle MD. Prescription opioid misuse, abuse, morbidity, and mortality: balancing effective pain management and safety. Pain Med. 2015;16(Suppl 1):S3–8.CrossRefPubMed Cheatle MD. Prescription opioid misuse, abuse, morbidity, and mortality: balancing effective pain management and safety. Pain Med. 2015;16(Suppl 1):S3–8.CrossRefPubMed
40.
go back to reference Ballantyne JC. Avoiding opioid analgesics for treatment of chronic low back pain. JAMA. 2016;315(22):2459–60.CrossRefPubMed Ballantyne JC. Avoiding opioid analgesics for treatment of chronic low back pain. JAMA. 2016;315(22):2459–60.CrossRefPubMed
41.
go back to reference Häuser W, Bock F, Engeser P, Tölle T, Willweber-Strumpfe A, Petzke F. Long-term opioid use in non-cancer pain. Dtsch Arztebl Int. 2014;111(43):732–40.PubMedPubMedCentral Häuser W, Bock F, Engeser P, Tölle T, Willweber-Strumpfe A, Petzke F. Long-term opioid use in non-cancer pain. Dtsch Arztebl Int. 2014;111(43):732–40.PubMedPubMedCentral
42.
go back to reference Els C, Jackson TD, Kunyk D, Lappi VG, Sonnenberg B, Hagtvedt R, Sharma S, Kolahdooz F, Straube S. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;10:CD012509.PubMed Els C, Jackson TD, Kunyk D, Lappi VG, Sonnenberg B, Hagtvedt R, Sharma S, Kolahdooz F, Straube S. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;10:CD012509.PubMed
43.
go back to reference Centers for Disease Control and Prevention Public Health Service US Department of Health and Human Services. Guideline for prescribing opioids for chronic pain. J Pain Palliat Care Pharmacother. 2016;30(2):138–40.CrossRef Centers for Disease Control and Prevention Public Health Service US Department of Health and Human Services. Guideline for prescribing opioids for chronic pain. J Pain Palliat Care Pharmacother. 2016;30(2):138–40.CrossRef
44.
go back to reference Manchikanti L, Abdi S, Atluri S, Balog CC, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15(3 Suppl):S67–116.PubMed Manchikanti L, Abdi S, Atluri S, Balog CC, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15(3 Suppl):S67–116.PubMed
45.
go back to reference Finnerup NB, Attal N, Haroutounian S, McNicol E, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.CrossRefPubMedPubMedCentral Finnerup NB, Attal N, Haroutounian S, McNicol E, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.CrossRefPubMedPubMedCentral
46.
go back to reference Dale R, Edwards J, Ballantyne J. Opioid risk assessment in palliative medicine. J Community Support Oncol. 2016;14(3):94–100.CrossRefPubMed Dale R, Edwards J, Ballantyne J. Opioid risk assessment in palliative medicine. J Community Support Oncol. 2016;14(3):94–100.CrossRefPubMed
47.
go back to reference Nuckols TK, Anderson L, Popescu I, Diamant AL, Doyle B, Di Capua P, Chou R. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160(1):38–47.CrossRefPubMed Nuckols TK, Anderson L, Popescu I, Diamant AL, Doyle B, Di Capua P, Chou R. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160(1):38–47.CrossRefPubMed
49.
go back to reference Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part I-evidence assessment American Society of Interventional Pain Physicians. Pain Physician. 2012;15(3 Suppl):1–65. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part I-evidence assessment American Society of Interventional Pain Physicians. Pain Physician. 2012;15(3 Suppl):1–65.
50.
51.
go back to reference Agarin T, Trescot AM, Agarin A, Lesanics D, Decastro C. Reducing opioid analgesic deaths in America: what health providers can do. Pain Physician. 2015;18(3):E307–22.PubMed Agarin T, Trescot AM, Agarin A, Lesanics D, Decastro C. Reducing opioid analgesic deaths in America: what health providers can do. Pain Physician. 2015;18(3):E307–22.PubMed
52.
go back to reference Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A, National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Physician. 2011;57(11):1269–76.PubMedPubMedCentral Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A, National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Physician. 2011;57(11):1269–76.PubMedPubMedCentral
53.
go back to reference Frank JW, Levy C, Matlock DD, Calcaterra SL, Mueller SR, Koester S, et al. Patients’ perspectives on tapering of chronic opioid therapy: a qualitative study. Pain Med. 2016;17:1838–47.CrossRefPubMed Frank JW, Levy C, Matlock DD, Calcaterra SL, Mueller SR, Koester S, et al. Patients’ perspectives on tapering of chronic opioid therapy: a qualitative study. Pain Med. 2016;17:1838–47.CrossRefPubMed
54.
go back to reference Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.CrossRefPubMed Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.CrossRefPubMed
55.
go back to reference Cobb B, Liu R, Valentine E, Onuoha O. Breastfeeding after anesthesia: a review for anesthesia providers regarding the transfer of medications into breast milk. Transl Perioper Pain Med. 2015;1:1–7.PubMedPubMedCentral Cobb B, Liu R, Valentine E, Onuoha O. Breastfeeding after anesthesia: a review for anesthesia providers regarding the transfer of medications into breast milk. Transl Perioper Pain Med. 2015;1:1–7.PubMedPubMedCentral
56.
go back to reference Chou R, Gordon DB, de Leon- Casasola OA, Rosenberg JM, Bickler S, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, executive committee, and administrative council. J Pain. 2016;17:131–57.CrossRefPubMed Chou R, Gordon DB, de Leon- Casasola OA, Rosenberg JM, Bickler S, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, executive committee, and administrative council. J Pain. 2016;17:131–57.CrossRefPubMed
58.
go back to reference Chou R, Turner JA, Devine EB. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276–86.CrossRefPubMed Chou R, Turner JA, Devine EB. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276–86.CrossRefPubMed
59.
go back to reference Volkow ND, Koroshetz W. Lack of evidence for benefit from long-term use of opioid analgesics for patients with neuropathy. JAMA Neurol. 2017;74(7):761–2.CrossRefPubMed Volkow ND, Koroshetz W. Lack of evidence for benefit from long-term use of opioid analgesics for patients with neuropathy. JAMA Neurol. 2017;74(7):761–2.CrossRefPubMed
60.
go back to reference Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–61.PubMed Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–61.PubMed
61.
go back to reference Low Y, Clarke CF, Huh BK. Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. Singapore Med J. 2012;53(5):357–60.PubMed Low Y, Clarke CF, Huh BK. Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. Singapore Med J. 2012;53(5):357–60.PubMed
62.
go back to reference Rivata C, Ballantyne J. The dark side of opioids in pain management: basic science explains clinical observation. Pain Rep. 2016;570:1–9. Rivata C, Ballantyne J. The dark side of opioids in pain management: basic science explains clinical observation. Pain Rep. 2016;570:1–9.
63.
go back to reference Weber L, Yeomans DC, Tzabazis A. Opioid-induced hyperalgesia in clinical anesthesia practice: what has remained from theoretical concepts and experimental studies. Curr Opin Anaesthesiol. 2017;30(4):458–65.CrossRefPubMed Weber L, Yeomans DC, Tzabazis A. Opioid-induced hyperalgesia in clinical anesthesia practice: what has remained from theoretical concepts and experimental studies. Curr Opin Anaesthesiol. 2017;30(4):458–65.CrossRefPubMed
64.
go back to reference Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Petrush K, Berman S, Sigmon SC. Opioid overdose experience, risk behaviors, and knowledge in drug users from a rural versus an urban setting. J Subst Abuse Treat. 2016;71:1–7.CrossRefPubMedPubMedCentral Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Petrush K, Berman S, Sigmon SC. Opioid overdose experience, risk behaviors, and knowledge in drug users from a rural versus an urban setting. J Subst Abuse Treat. 2016;71:1–7.CrossRefPubMedPubMedCentral
65.
go back to reference Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, Han JJI. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abuse Rehabil. 2016;7:131–41.CrossRefPubMedPubMedCentral Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, Han JJI. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abuse Rehabil. 2016;7:131–41.CrossRefPubMedPubMedCentral
66.
go back to reference Chou R, Deyo R, Devine B et al. The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence report/technology assessment no. 218. (Prepared by the Pacific Northwest Evidence-based Practice Center under contract no. 290-2012-00014-I). AHRQ publication no. 14-E005- EF. Rockville, MD: Agency for Healthcare Research and Quality (2014). http://www.effectivehealthcare.ahrq.gov. Chou R, Deyo R, Devine B et al. The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence report/technology assessment no. 218. (Prepared by the Pacific Northwest Evidence-based Practice Center under contract no. 290-2012-00014-I). AHRQ publication no. 14-E005- EF. Rockville, MD: Agency for Healthcare Research and Quality (2014). http://​www.​effectivehealthc​are.​ahrq.​gov.
67.
go back to reference Peck KR, Ehrentraut JH, Anghelescu DL. Risk factors for opioid misuse in adolescents and young adults with focus on oncology setting. J Opioid Manag. 2016;12(3):2015–6. Peck KR, Ehrentraut JH, Anghelescu DL. Risk factors for opioid misuse in adolescents and young adults with focus on oncology setting. J Opioid Manag. 2016;12(3):2015–6.
68.
go back to reference Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Consensus Report, National Academy of Sciences, July 2017. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Consensus Report, National Academy of Sciences, July 2017.
69.
go back to reference Vissers KCP, Besse K, Hans G, Devulder J, Morlion B. Opioid rotation in the management of chronic pain: where is the evidence. Pain Pract. 2010;10(2):85–93.CrossRefPubMed Vissers KCP, Besse K, Hans G, Devulder J, Morlion B. Opioid rotation in the management of chronic pain: where is the evidence. Pain Pract. 2010;10(2):85–93.CrossRefPubMed
70.
go back to reference Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States. MMWR Morb Mortal Wkly. 2016;65:1–49. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States. MMWR Morb Mortal Wkly. 2016;65:1–49.
71.
go back to reference Bonnie RJ, Kesselheim AS, Clark DJ. Both urgency and balance needed in addressing opioid epidemic: a report from the National Academies of Sciences, Engineering, and Medicine. JAMA. 2017;318(5):423–4.CrossRefPubMed Bonnie RJ, Kesselheim AS, Clark DJ. Both urgency and balance needed in addressing opioid epidemic: a report from the National Academies of Sciences, Engineering, and Medicine. JAMA. 2017;318(5):423–4.CrossRefPubMed
72.
go back to reference Frank JW, Lovejoy TI, Becker WC, Morasco BJ, Koenig CJ, Hoffecker L, Dischinger HR, Dobscha SK, Krebs EE. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review. Ann Intern Med. 2017;167(3):181–91.CrossRefPubMed Frank JW, Lovejoy TI, Becker WC, Morasco BJ, Koenig CJ, Hoffecker L, Dischinger HR, Dobscha SK, Krebs EE. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review. Ann Intern Med. 2017;167(3):181–91.CrossRefPubMed
73.
go back to reference Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. Mayo Clin Proc. 2015;90:828–42.CrossRefPubMed Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. Mayo Clin Proc. 2015;90:828–42.CrossRefPubMed
74.
go back to reference Ihongbe TO, Masho SW. Prevalence, correlates and patterns of heroin use among young adults in the United States. Addict Behav. 2016;63:74–81.CrossRefPubMed Ihongbe TO, Masho SW. Prevalence, correlates and patterns of heroin use among young adults in the United States. Addict Behav. 2016;63:74–81.CrossRefPubMed
75.
go back to reference Webster JR, Markman J, Cone EJ, Niebler G. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgrad Med. 2017;129(1):102–10.CrossRefPubMed Webster JR, Markman J, Cone EJ, Niebler G. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgrad Med. 2017;129(1):102–10.CrossRefPubMed
77.
go back to reference Blanch B, Buckley NA, Mellish L, Dawson AH, Haber PS, Pearson SA. Harmonizing post-market surveillance of prescription drug misuse: a systematic review of observational studies using routinely collected data (2000–2013). Drug Saf. 2015;38(6):553–604.CrossRefPubMed Blanch B, Buckley NA, Mellish L, Dawson AH, Haber PS, Pearson SA. Harmonizing post-market surveillance of prescription drug misuse: a systematic review of observational studies using routinely collected data (2000–2013). Drug Saf. 2015;38(6):553–604.CrossRefPubMed
78.
go back to reference Modesto-Lowe V, Swiezbin K, Chaplin M, Hoefer G. Use and misuse of opioid agonists in opioid addiction. Cleve Clin J Med. 2017;84(5):377–84.CrossRefPubMed Modesto-Lowe V, Swiezbin K, Chaplin M, Hoefer G. Use and misuse of opioid agonists in opioid addiction. Cleve Clin J Med. 2017;84(5):377–84.CrossRefPubMed
79.
go back to reference Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391–4.CrossRefPubMed Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391–4.CrossRefPubMed
80.
go back to reference Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly. 2016;64(50–55):1378–82.CrossRef Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly. 2016;64(50–55):1378–82.CrossRef
81.
go back to reference Pergolizzi JV Jr, LeQuang JA. Abuse-deterrent formulations of opioid analgesics. Pain Pract. 2014;14(3):204–6.CrossRefPubMed Pergolizzi JV Jr, LeQuang JA. Abuse-deterrent formulations of opioid analgesics. Pain Pract. 2014;14(3):204–6.CrossRefPubMed
82.
go back to reference Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus. 2015;36(2):240–53.CrossRefPubMedPubMedCentral Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus. 2015;36(2):240–53.CrossRefPubMedPubMedCentral
Metadata
Title
A Review of the Opioid Epidemic: What Do We Do About It?
Authors
Edward A. Shipton
Elspeth E. Shipton
Ashleigh J. Shipton
Publication date
01-06-2018
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 1/2018
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-018-0096-7

Other articles of this Issue 1/2018

Pain and Therapy 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.